894851-71-9Relevant academic research and scientific papers
CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF
-
Paragraph 0507-0510, (2021/11/13)
Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
CB2-selective cannabinoid receptor ligands: Synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-naphthyridin-2(1 H)-one-3-carboxamides
Lucchesi, Valentina,Hurst, Dow P.,Shore, Derek M.,Bertini, Simone,Ehrmann, Brandie M.,Allarà, Marco,Lawrence, Lyle,Ligresti, Alessia,Minutolo, Filippo,Saccomanni, Giuseppe,Sharir, Haleli,Macchia, Marco,Di Marzo, Vincenzo,Abood, Mary E.,Reggio, Patricia H.,Manera, Clementina
, p. 8777 - 8791 (2015/03/14)
We have recently identified 1,8-naphthyridin-2(1H)-one-3-carboxamide as a new scaffold very suitable for the development of new CB2 receptor potent and selective ligands. In this paper we describe a number of additional derivatives in which the same central scaffold has been variously functionalized in position 1 or 6. All new compounds showed high selectivity and affinity in the nanomolar range for the CB2 receptor. Furthermore, we found that their functional activity is controlled by the presence of the substituents at position C-6 of the naphthyridine scaffold. In fact, the introduction of substituents in this position determined a functionality switch from agonist to antagonists/inverse agonists. Finally, docking studies showed that the difference between the pharmacology of these ligands may be in the ability/inability to block the Toggle Switch W6.48(258) (χ1 g+ → trans) transition.
NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE
-
Page/Page column 39-40; 106, (2013/10/22)
Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 112, (2010/11/27)
In part, the present invention is directed to antibacterial compounds
